Vericiguat reduced the incidence of cardiovascular death or heart failure hospitalization among high-risk patients compared to placebo.
Does vericiguat reduce the incidence of death from cardiovascular causes or hospitalization for heart failure in patients with high-risk heart failure and reduced ejection fraction?
Vericiguat reduces the composite of cardiovascular death or heart failure hospitalization in patients with high-risk heart failure and reduced ejection fraction compared to placebo.
Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo. (Funded by Merck Sharp VICTORIA ClinicalTrials.gov number, NCT02861534.).
Armstrong et al. (2020) studied this question. Vericiguat reduced the incidence of cardiovascular death or heart failure hospitalization among high-risk patients compared to placebo.